Zoetis Inc. $ZTS Shares Bought by MQS Management LLC

MQS Management LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 65.2% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,240 shares of the company’s stock after buying an additional 1,674 shares during the quarter. MQS Management LLC’s holdings in Zoetis were worth $661,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Zoetis in the first quarter valued at about $616,375,000. Mackenzie Financial Corp raised its stake in shares of Zoetis by 4,158.3% during the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after buying an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC lifted its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the period. Amundi lifted its holdings in shares of Zoetis by 30.8% in the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after buying an additional 846,909 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd boosted its stake in shares of Zoetis by 475.9% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after buying an additional 743,926 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $146.14 on Friday. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $184.40. The stock has a market cap of $64.77 billion, a P/E ratio of 25.15, a PEG ratio of 2.35 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a 50-day moving average of $148.18 and a two-hundred day moving average of $153.57.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the business earned $1.56 earnings per share. The company’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is presently 34.42%.

Analyst Ratings Changes

Several research analysts have issued reports on ZTS shares. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Friday. UBS Group decreased their price objective on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a report on Monday, October 20th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Finally, Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.